PDCD1 and breast carcinoma: Although immunotherapy with immune checkpoints (such as PD-1 (programmed cell death protein 1) and PDL-1 (PD-1 ligand 1) antibodies) has shown some efficacy in many solid tumors, including breast cancer, clinical data in TNBC suggest significant limitations5–7.